Indonesia With a market value of USD 5.2 billion, Kalbe Farma has consolidated into Indonesia’s undisputed national pharma champion and has established a footprint in many ASEAN countries as well as in Africa. Today, the largest publicly listed pharmaceutical company in Southeast Asia is aiming to seize on their COVID-19-related partnership…
Denmark On April 16, the Danish government unveiled, to great anticipation and fanfare, a brand-new National Life Science Strategy which seeks to chart the course for the next three years of an industry sector that has become increasingly influential for the country’s economy. Indeed, Denmark’s healthcare and life sciences segment now…
Egypt As of today, the Evergreen boat that blocked global shipping when it got stuck in the Suez Canal has still not been allowed to leave Egypt. The infamous episode illustrated the complex situation that has affected global economies during the pandemic. But, for Egypt, the liberation of the canal symbolized…
Switzerland Thomas A. Tóth von Kiskér, longstanding CEO of Tillotts Pharma AG, a specialty pharma player focused on the digestive system, has overseen a number of acquisitions and the growth of the company from 30 to 300 employees. Here, he shares his insights on why M&A may be a better strategy…
China Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation with Sanofi China’s Irene Deng, looks at how Chinese pharmaceutical regulations have evolved and what impact this has had on regulatory professionals in the country. The Chinese pharmaceutical industry, through the first five…
Saudi Arabia Lilly Saudi Arabia’s Dimitri Livadas shares some of the misconceptions he had before moving to the Kingdom a couple of years ago, highlights the evolution of the Saudi healthcare system with its current focus on digital health, the big opportunities for the Indiana-based company’s diabetes portfolio at a moment when…
Saudi Arabia Amgen’s Middle East and Africa General Manager Mohamed Nasser discusses the company’s approach to the region; the opportunities in the Saudi market, given its improved regulatory environment; and the disadvantages of its reference pricing system. In addition, Nasser explains Amgen’s approach to Saudization and the company’s place within Saudi Arabia’s…
Saudi Arabia Georg Schroeckenfuchs, Novartis’ president MEA and head of its Gulf and Saudi Country Group, explains how the company’s objectives are aligned with Saudi Arabia’s Vision 2030, the progress made towards the nationalization of its Saudi workforce, the potential impact of changes in the tender process, and why Novartis is uniquely…
Pharma Legal Handbook Regulatory reforms to watch out for in Portuguese pharma. Prepared in association with Cuatrecasas, a leading law firm in Portugal, this is an extract from The Pharma Legal Handbook: Portugal, available to purchase here for GBP 99. 1. Are there proposals for reform or significant change to the healthcare system?…
Pharma Legal Handbook All legal aspects surrounding cannabinoid drugs, medicinal cannabis and opioid drugs in Portugal. Prepared in association with Cuatrecasas, a leading Iberian law firm, this is an extract from The Pharma Legal Handbook: Portugal, available to purchase here for GBP 99. Cannabinoid Drugs 1. Are Cannabinoid Drugs authorized in your…
Pharma Legal Handbook An intro to the legal situation for orphan drugs and rare diseases in Portugal. Prepared in association with Cuatrecasas, a leading Iberian law firm, this is an extract from The Pharma Legal Handbook: Portugal, available to purchase here for GBP 99. 1. What is the definition of Rare…
China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.” We want…
See our Cookie Privacy Policy Here
